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https://doi.org/10.1016/j.ccell.2019.12.012SUMMARYThe TIGAR protein has antioxidant activity that supports intestinal tissue repair and adenoma development.
Using a pancreatic ductal adenocarcinoma (PDAC)model, we show that reactive oxygen species (ROS) regu-
lation by TIGAR supports premalignant tumor initiation while restricting metastasis. Increased ROS in PDAC
cells drives a phenotypic switch that increases migration, invasion, and metastatic capacity. This switch is
dependent on increased activation of MAPK signaling and can be reverted by antioxidant treatment. In
mouse and human, TIGAR expression is modulated during PDAC development, with higher TIGAR levels
in premalignant lesions and lower TIGAR levels in metastasizing tumors. Our study indicates that temporal,
dynamic control of ROS underpins full malignant progression and helps to rationalize conflicting reports of
pro- and anti-tumor effects of antioxidant treatment.INTRODUCTION
Reactive oxygen species (ROS) play important and diverse roles
in regulating many aspects of cell behavior, from signaling prolif-
eration and survival to promotion of oxidative damage and cell
death. Not surprisingly, therefore, control of ROS production
and defects in antioxidant defense have been associated with
many aspects of human health and disease (Schieber and Chan-
del, 2014). The contribution of ROS to cancer development
has been somewhat controversial and is clearly highly complex.
Numerous lines of evidence support the concept that ROS
contribute to cancer initiation and development. ROS can induce
both genotoxic damage and chronic inflammation (Feig et al.,
1994; Tafani et al., 2016), while membrane-associated ROS
generated through NADPH oxidases (such as NOX4) are
important contributors to the activation of signaling pathwaysSignificance
Many studies and clinical trials have shown ROS to both enhan
the effects of ROS over the full course of development of a si
model we show that ROS limitation by the antioxidant protein
while ROS promotion can drive increased metastasis through
tumor invasiveness are reversible, allowing for the dynamic s
back. This work rationalizes the complexity of ROS regulation
of antioxidants in cancer therapy.
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This is an open access article under the CC BY license (http://creativethat drive proliferation and metastasis (Saikolappan et al.,
2019). Furthermore, mitochondrial ROS were also shown to be
necessary for KRAS-induced cancer development (Weinberg
et al., 2010). It was therefore surprising that no beneficial effect
of antioxidants was detected in cancer prevention studies,
some of which even revealed an increase in cancer development
in the antioxidant-treated group (Alpha-Tocopherol and Beta
Carotene Cancer Prevention Study Group, 1994; Klein et al.,
2011). Subsequent work has shown that many of the steps
involved in malignant progression are associated with increased
oxidative stress and an increased sensitivity of cells to succumb
to ROS-induced death (Gorrini et al., 2013). Activation of antiox-
idant defense pathways is critical for successful tumor develop-
ment, leading to a revised model in which ROS limitation may
function to enhance tumorigenesis. Many studies have now sup-
ported the concept that tumor cells inherently carry a highce and retard tumor progression. This study seeks to clarify
ngle tumor type, pancreatic ductal adenocarcinoma. In this
TIGAR is important for the development of premalignancies,
activation of ERK. We also show that the effects of ROS on
witching from a proliferative to an invasive phenotype, and
during cancer progression and may help to guide the use
. Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
Figure 1. Tigar Deletion Reduces Proliferation and PanIN-Precursor Lesions in KRAS-Driven Ductal Adenocarcinoma (PDAC) and Reduces
Cell Survival after Oxidative Stress In Vitro
(A and B) H&E staining of pancreas lesions (A) and quantification (B) of PanIN from control (CTR) and Tigar-deficient (KO) KC mice (CTR, Pdx1-Cre;LSL-
KrasG12D/+;Tigar+/+ or Tigarfl/+ [n = 6]; KO, Pdx1-Cre;LSL-KrasG12D/+;Tigarfl/fl [n = 5]) at 240 days. *p < 0.05 compared with CTR.
(C and D) Ki67 staining at 240 days (C) and number of Ki67-positive cells at indicated ages (D) of CTR and KO KC pancreas. *p < 0.05 compared with CTR.
(legend continued on next page)
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burden of oxidative stress, reflecting abnormal oncogenic
signaling and loss of normal environment. Survival of these cells
depends on a concomitant increase in ROS scavenging path-
ways that is not needed in normal cells, suggesting that interfer-
ence with these antioxidant pathways or simply additional
ROS burden may selectively kill cancer cells. Interestingly,
many commonly used chemotherapeutic agents effectively
induce ROS (Chandel and Tuveson, 2014; Gorrini et al., 2013).
Many mechanisms through which tumor cells limit ROS expo-
sure have been described. One of the most ubiquitous is the
activation of NRF2, a transcription factor that regulates a pro-
gram of genes involved in antioxidant defense. Activation of
oncogenes such as KRAS or environmental signals such as
lack of oxygen (hypoxia) can induce NRF2, with evidence that
this response is necessary for tumor development (DeNicola
et al., 2011; Mitsuishi et al., 2012). Direct activation of NRF2
through overexpression of the protein or loss of the negative
regulator KEAP1 is frequent in cancer development (Rojo de la
Vega et al., 2018). Another protein that contributes to ROS limi-
tation is TIGAR, a protein with bisphosphatase activity that can
support the activation of the oxidative pentose phosphate
pathway (PPP) in response to oxidative stress and so enhance
the production of NADPH for antioxidant defense (Bensaad
et al., 2006; Cheung et al., 2013). Functions of TIGAR that limit
ROS have been shown to contribute to damage resolution in
intestinal epithelium and protect from pathologies such as
cerebral ischemia (Cheung et al., 2013; Li et al., 2014). However,
elevated expression of TIGAR has also been detected in many
cancer types, consistent with a role for antioxidants in tumor
progression (Lee et al., 2014). In mice, loss of TIGAR leads to
increased survival and slower tumor development in intestinal
and lymphoma models (Cheung et al., 2013; Maddocks
et al., 2017).
While ROS limitation has a clear role in supporting cancer
development, the contribution of ROS to different stages of
cancer development remains unclear. Early studies suggested
that increased ROS may be linked to enhanced metastasis (Ar-
nandis et al., 2018; Arora et al., 2013; Goh et al., 2011; Ishikawa
et al., 2008; O’Leary et al., 2015; Porporato et al., 2014; Radisky
et al., 2005). However, several recent studies in melanoma and
other tumor types have elegantly demonstrated an importance
of ROS limitation in allowing metastatic spread (Le Gal et al.,
2015; Lignitto et al., 2019; Piskounova et al., 2015; Sayin et al.,
2014; Wiel et al., 2019). These observations are consistent with
studies showing that detachment of cells from the extracellular
matrix (Debnath et al., 2002), as may occur when cells leave
the primary tumor site and enter the circulation, results in
increased ROS, which is limited by various metabolic adapta-
tions. These recent data have led to the suggestion that ROS(E and F) H&E staining of pancreas lesions (E) and quantification (F) of PanIN from
[n = 9]; KO, Pdx1-Cre;LSL-KrasG12D/+;Trp53fl/+;Tigarfl/fl [n = 4]) mice at 70 days. *
(G and H) Ki67 staining at 70 days (G) and number of Ki67-positive cells at indica
(I and J) MDA staining (I) and quantification (J) of CTR and KO KC pancreas at 2
(K and L) MDA staining (K) and quantification (L) of CTR and KO KFC pancreas a
(M) Cell death of CTR (C1–3) and TIGAR KO (K1–3) KFC PDAC cell lines 24 h after A
TIGAR (5 mg/mL). *p < 0.05 Adriamycin-treated K1–3 compared with Adriamycin
dependent experiments for each cell line.
Error bars represent mean ± SEM. Data analyzed by unpaired Student’s t test betw
test (M). Scale bar, 100 mm. See also Figure S1.
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development (Assi, 2017), a model supported by studies in
melanoma (Bagati et al., 2019; Le Gal et al., 2015; Piskounova
et al., 2015).
In this study, we examine the role of TIGAR in the development
of pancreatic cancer. Using mutant KRAS-driven pancreatic
ductal adenocarcinoma (PDAC) mouse models, we show that
loss of TIGAR delays the emergence of premalignant pancreatic
intraepithelial neoplasia (PanIN) lesions, but enhances the meta-
static capacity of the tumor cells, leading to decreased survival.
Tigar null tumors and cells showhigher ROS levels and increased
mesenchymal characteristics, accompanied by enhanced
capacity for migration and invasion. The responses to loss of
TIGAR are plastic and reverted by treatment of cells with antiox-
idants. Consistently, the pattern of TIGAR expression in both
human andmouse PDACs also suggests a role for ROS limitation
in the establishment of the primary malignancy and distant
metastasis, with a role for enhanced ROS during the process
of metastatic spread.
RESULTS
Tigar Deletion in KRAS-Driven Pancreatic Cancer
Increases ROS and Limits Early Tumor Progression
To examine the role of TIGAR in the development of PDAC, we
utilized well-established mouse models that use Pdx1-Cre to
drive pancreas expression of mutant KRAS (LSL-KrasG12D/+)
alone (KC) or mutant KRAS with mutant p53 (LSL-p53R172H/+;
KPC) or with loss of p53 (p53fl/+; KFC). In the KFC model,
CRE-mediated deletion of one p53 allele is accompanied by
loss of the remaining wild-type allele during tumor development
(Hingorani et al., 2005). Each of these models was crossed into a
Tigarfl/fl strain to generate pancreatic tumors that retained Tigar
expression (CTR) or deleted (KO) for Tigar. Initial analysis of pre-
neoplastic PanIN in the KCmodel showed that loss of TIGAR de-
layed the appearance of each stage of PanIN progression
(PanIN1, 2, and 3), accompanied by lower proliferation in the Ti-
gar null lesions, measured by Ki67 staining (Figures 1A–1D). Us-
ing the KFC model, PanIN lesions were detected more rapidly,
and again, the loss of TIGAR retarded the appearance of PanIN
and lowered proliferation of these preneoplastic lesions (Figures
1E–1H). These results are consistent with our work showing
that loss of TIGAR delayed the appearance of intestinal ade-
nomas in response to APC loss and previous work showing
decreased PanIN development following loss of the antioxidant
factor NRF2 in a PDAC model (Cheung et al., 2013; DeNicola
et al., 2011). Using anti-malondialdehyde (MDA) staining of
peroxidized lipids as a marker of oxidative stress, we confirmed
an increase of ROS in the Tigar KO PanINs (in the KC and KFCCTR and KO KFC (CTR, Pdx1-Cre;LSL-KrasG12D/+;Trp53fl/+;Tigar+/+ or Tigarfl/+
p < 0.05 compared with CTR.
ted ages (H) of CTR and KO KFC pancreas. *p < 0.05 compared with CTR.
40 days. *p < 0.05 compared with CTR.
t endpoint. *p < 0.05 compared with CTR.
driamycin (1 mg/mL) treatment alone or with either NAC (1 mM) or recombinant
-treated C1–3, **p < 0.05 compared with Adriamycin-treated K1–3. n = 3 in-
een CTR and KO (B, D, F, H, J, and L) or one-way ANOVAwith Tukey post hoc
Figure 2. Tigar or Nrf2 Deletion Promotes Invasion and Metastasis in KRAS-Driven Pancreatic Ductal Adenocarcinoma
(A) Disease-free survival in mutant p53-driven PDAC (KPC) with and without TIGAR (CTR, Pdx1-Cre;KrasG12D/+;Trp53R172H/+;Tigar+/+ or Tigarfl/+ [n = 30]; KO,
Pdx1-Cre;KrasG12D/+;Trp53R172H/+;Tigarfl/fl [n = 28]). MS, median survival in days.
(B) Disease-free survival in p53-deficient-driven PDAC (KFC) with and without TIGAR (CTR, Pdx1-Cre;KrasG12D/+;Trp53fl/+;Tigar+/+ or Tigarfl/+ [n = 35]; KO, Pdx1-
Cre;KrasG12D/+;Trp53fl/+;Tigarfl/fl [n = 33]). MS, median survival in days.
(C) Numbers of CTR and KO KPC animals with and without metastasis.
(D) Numbers of CTR and KO KFC animals with and without metastasis.
(E) Number of lung and liver metastases in Tigar control (CTR) and Tigar-deficient (KO) KFC animals.
(F) H&E staining of Tigar-deficient KPC tissues with metastasis (denoted by asterisks). Scale bar, 100 mm.
(G) H&E staining of Tigar-deficient KFC tissues with metastasis (denoted by asterisks). Scale bar, 100 mm.
(H) Overall survival of KPC animals (expressing R270H mutant p53) with (Nrf2+/+, n = 34) and without NRF2 (Nrf2/, n = 25).
(I) Thenumberof lungand/or livermetastases inNRF2wild-type (Nrf2+/+) andNRF2-deficient (Nrf2/) KPCanimals (16of 21NRF2wild-typeand12of 13NRF2-deficient
micewithPDAC (FigureS2D)wereexamined). Liver= numberofmicewithmacroscopicmetastases in liver; lung=numberofmicewithmacroscopicmetastases in lung;
macro = number of mice with macroscopic metastases (lung and/or liver); total = mice with macroscopic and/or microscopic metastases in lung and/or liver.
Data in (A), (B), and (H) were analyzed by log rank test. Data in (C)–(E) were analyzed by Fisher’s exact test. See also Figure S2.
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Figure 3. Tigar Deletion Promotes Epithelial to Mesenchymal-like Phenotype in PDAC
(A and B) E-CADHERIN staining (A) and quantification (B) of CTR and TIGAR KO (KO) KFC tumors. *p < 0.05 compared with CTR.
(C and D) VIMENTIN staining (C) and quantification (D) of CTR and KO KFC tumors. *p < 0.05 compared with CTR.
(E and F) SLUG staining (E) and quantification (F) of CTR and KO KFC tumors. *p < 0.05 compared with CTR.
(G) Photomicrographs of isolated PDAC cell lines of CTR (from C1–3) and KO (from K1–3) primary KFC tumors.
(H)Western blot analysis of isolated CTR and KOKFCPDAC cell lines. E-CAD, SLUG, TIGAR, and the loading control VINCULINwere detected on one blot, SNAIL
and the loading control ACTIN were detected on a separate parallel blot.
(legend continued on next page)
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models) aswell as TigarKOPDAC (in the KFCmodel) (Figures 1I–
1L). Cell lines were derived from tumors from three Tigar wild-
type (C1, C2, C3) and three Tigar-deleted (K1, K2, K3) KFC
mice. Consistent with an antioxidant role for TIGAR,
mitochondrial ROS levels were increased in the Tigar KO cell
lines and could be lowered by treatment with the antioxidant
N-acetyl-L-cysteine (NAC) (Figure S1A). The Tigar KO cells
also showed increased death following exposure to the ROS-
inducing chemotherapeutic Adriamycin (Doxorubicin), which
was limited by treatment with NAC (Figure 1M). Importantly,
introduction of recombinant TIGAR to the Tigar null cells (Fig-
ure S1B), which decreased ROS levels in Tigar KO cells (Fig-
ure S1C), also rescued the sensitivity to Adriamycin (Figure 1M).
TIGAR has been shown to support flux through the oxidative
PPP, which generates NADPH for antioxidant defense (Li et al.,
2014). Both oxidative and non-oxidative PPPs produce ribose
5-phosphate (R5P), and previous studies have shown that these
mutant KRAS-expressing PDACs increase R5P generation
through the non-oxidative pathway (Ying et al., 2012). Interest-
ingly, no consistent differences in R5P levels were detected
between Tigar wild-type or null cells (Figure S1D), suggesting
that any defect in oxidative PPP in Tigar null cells is compen-
sated for by an increase in non-oxidative PPP flux. Taken
together, these results show that TIGAR limits oxidative stress,
a function that correlates with the ability of TIGAR to support
the initial stages of PDAC development.
Tigar Deletion in PDAC Promotes Metastasis and Limits
Survival
Whereas tumors in the KC mice progress rather slowly, PDAC
development is more rapid in KFC and KPC mice (Hezel et al.,
2006; Hruban et al., 2006). Surprisingly, however, despite the
delay in PanIN development, loss of TIGAR reduced survival of
both KPC and KFC mice (Figures 2A and 2B). This reduced
survival was not reflected in any obvious difference in the differ-
entiation status of CTR and KO primary tumors (Figure S2A), but
was accompanied by widespread tumor dissemination to
multiple organs. Staining for CK-19 confirmed that the lung le-
sions represented metastatic spread of PDAC (Figure S2B). In
the KPC model, where most CTR mice showed evidence of
metastases (Hingorani et al., 2005; Hruban et al., 2006), the addi-
tional effect of TIGAR loss did not reach significance (Figure 2C).
Nevertheless, the total number of organs showing evidence of
metastasis was significantly increased by Tigar deletion (Figures
2F and S2C). In the less metastatic KFC model, loss of TIGAR
resulted in significantly more mice carrying metastases (Figures
2D and 2G), with a striking increase in the number of lung lesions
(Figure 2E). In support of these observations, loss of the antiox-
idant defense protein NRF2 in KPC tumors (which has been
shown to reduce PanIN development due to increase of ROS;
DeNicola et al., 2011) also failed to extend overall survival (Fig-
ure 2H) and PDAC-free survival (Figure S2D) and instead pro-
moted increased lung metastases (Figure 2I). (In this NRF2
KPC model, the mutant p53 allele was LSL-p53R270H.) Taken(I) Immunofluorescence of isolated CTR and KO KFC PDAC cell lines.
(J) Representative images of wound-scratch assay of CTR and KO KFC PDAC c
(K) Representative images of transwell migration and invasion assays of CTR an
(B, D, and F) Error bars represent mean ± SEM, and data were analyzed by two-together, our data indicate that increased oxidative stress due
to loss of TIGAR in KFC and KPC pancreas cancer models de-
lays initial tumor development but enhances metastatic progres-
sion at later stages.
Previous studies have shown that metastatic capacity in
PDAC tumors is associated with the acquisition of a more
mesenchymal phenotype. While the exact contribution of
various drivers of epithelial-mesenchymal transition (EMT) has
been a topic of discussion (Aiello et al., 2017; Zheng et al.,
2015), more recent data support the importance of a switch
from an epithelial phenotype—characterized by E-CADHERIN
staining—to a more mesenchymal, VIMENTIN-positive appear-
ance of the cancer cells in driving PDAC metastasis (Krebs
et al., 2017). Histological analysis of KFC tumors null for Tigar
(KO) showed a reduction of E-CADHERIN expression (Figures
3A and 3B) and an increase in VIMENTIN expression (Figures
3C and 3D) compared with KFC tumors that retained TIGAR
expression (CTR). This shift in phenotype corresponded with
increased expression of the mesenchymal marker SLUG in the
KO tumors (Figures 3E and 3F). In support of these observations,
loss of the antioxidant protein NRF2 also led to a reduction
in E-CADHERIN expression (Figures S3A and S3B) and an
increase in SLUG expression (Figures S3C and S3D) in PDAC tu-
mors. In culture, cell lines derived from Tigar null KFC tumors
also showed a clear shift to a more mesenchymal phenotype
(Figure 3G), losing E-CADHERIN expression while gaining
expression of SLUG and SNAIL (another marker associated
with amesenchymal phenotype) (Lu andKang, 2019) (Figure 3H).
Immunofluorescence analysis confirmed the switch from
E-CADHERIN to VIMENTIN expression in the Tigar null PDAC
cells (Figure 3I). Consistent with the acquisition of a mesen-
chymal phenotype and increase in metastasis, Tigar null cells
showed an increased rate of wound healing in a scratch assay
(Figure 3J) and increased migration and invasion in transwell as-
says (Figure 3K). Reintroduction of exogenous TIGAR in these
cells reversed the enhanced invasion (Figures S3G and S3H).
These results indicate that TIGAR deficiency allows PDAC cells
to increase invasiveness and switch to a more mesenchymal
phenotype.
TIGAR Deficiency Promotes Activation of Erk Signaling
that Supports the Invasive Phenotype
Previous studies have described numerous mechanisms
responsible for the switch to a mesenchymal phenotype in met-
astatic and therapy-resistant tumor cells, several of which have
been shown to be induced by increased ROS (Giannoni et al.,
2012; Yang et al., 2014). Analysis of pNF-kB, pSRC, pSTAT3,
pAKT, and HO1 expression failed to demonstrate a convincing
and consistent upregulation of the NF-kB, SRC, STAT3, AKT,
or hypoxia pathway in the Tigar KO cells compared with CTR
cells (Figure S4A). Furthermore, there were no consistent
changes in the expression of proteins encoded by HIF1 target
genes such as GLUT1 and BNIP3 (Figure S4B). Previous studies
have suggested that depletion of TIGAR results in a decrease inell lines.
d KO KFC PDAC cell lines.
tailed Student’s t test. Scale bar, 100 mm. See also Figure S3.
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Figure 4. Tigar Deficiency Promotes Activation of a Pro-migratory Erk Signaling
(A) Western blot analysis of CTR and TIGAR KO KFC PDAC cells. pERK, ERK, TIGAR, and the loading control VINCULIN were detected on one blot, DUSP6 and
the loading control VINCULIN (bottom) were detected on a separate parallel blot.
(B and C) Phospho-ERK (pERK) staining (B) and quantification (C) of CTR and TIGAR KO KFC tumors. *p < 0.05 KO compared with CTR.
(D and E) DUSP6 staining (D) and quantification (E) of CTR and TIGAR KO KFC tumors. *p < 0.05 KO compared with CTR.
(legend continued on next page)
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MET expression in lung cancer cell lines (Shen et al., 2018), but
we were unable to detect any difference in MET expression in
our PDAC cells (Figure S4B). Recent studies have also shown
that increased ROS lead to the degradation of BACH1 to limit
metastasis (Wiel et al., 2019), but this was not evident in the
TIGAR null PDAC cells (Figure S4B). These data suggest that
direct regulation of MET or BACH1 expression does not play a
role in the response to loss of TIGAR in our model, although
they do not preclude a more general involvement of these
signaling pathways. By contrast, a clear increase in phosphory-
lated ERK was seen in Tigar KO cells, accompanied by a
decreased expression of DUSP6/MKP-3, the phosphatase
responsible for dephosphorylating and inactivating ERK (Groom
et al., 1996;Muda et al., 1996) (Figure 4A). This shift in expression
correlated with the switch from E-CADHERIN to VIMENTIN
expression in these cells (Figure 3I). A similar increase in pERK
and decrease in DUSP63 expression was also seen in the
PDAC lesions in vivo (Figures 4B–4E). Consistently, inhibition
of the ERK signaling pathway using the MAPKK inhibitor
PD98059 (Pang et al., 1995) led to a reversion of Tigar null
PDAC cells to a more epithelial phenotype (Figure S4C). Further-
more, a similar increase in phospho-ERK (Figures S3E and S3F)
was also observed in NRF2 null PDAC tumors.
To determine the effect of ERK activation on the invasive ca-
pacity of Tigar KO PDAC cells, we treated the cells with the
ERK pathway inhibitor PD98059. The enhanced wound closure,
migration, and invasion seen in cells derived from Tigar null
PDACs were significantly decreased in PD98059 treated cells
(Figures 4F–4K). Tigar null tumor cells showed an increased
collagen-degrading activity indicative of increased invadopodia
function (Figures 4L and 4M) that was also dependent on ERK
pathway activity. To confirm the contribution of ERK in driving
invasion,we showeddecreasedmigration ofTigar null PDACcells
depleted of ERK by small interfering RNA (Figures S4D–S4F). Re-
expressing DUSP6 in Tigar null cells decreased ERK phosphory-
lation (Figure S4G), as expected, and also decreased the migra-
tion of these TIGAR-deficient cells (Figures 4N and 4O). These
data are consistent with a model in which Tigar null PDAC cells
enhance MAPK signaling through a decrease in DUSP6 expres-
sion, which drives enhanced migration.
The Role of ROS in TIGAR-Deficiency-Induced Pro-
migratory Phenotypes
Having shown increased ROS levels in tumors and cell lines
deficient in TIGAR (Figures 1I–1L and S1A) and enhanced(F and G) Representative images (F) and quantification (G) of wound-scratch ass
vehicle treatment) MAPK kinase inhibitor PD98059 (PD; 50 mM). *p < 0.05 K1–3
PD (CTR).
(H and I) Representative images (H) and quantification (I) of transwell migration as
vehicle treatment) PD98059. *p < 0.05 K1–3 compared with C1–3, **p < 0.05 K1
(J and K) Representative images (J) and quantification (K) of transwell invasion as
vehicle treatment) PD98059. *p < 0.05 K1–3 compared with C1–3, **p < 0.05 K1
(L and M) Representative images (red, phalloidin; green, nuclei; white, fluorescen
TIGAR KO KFC PDAC cells with or without (CTR, no treatment) PD98059. *p < 0
without PD.
(N andO) Representative images (N) and quantification (O) of transwell migration a
overexpression of DUSP6. *p < 0.05 K1–3 compared with C1–3, **p < 0.05 K1–3
Error bars represent mean ± SEM. (G, I, K, M, and O) n = 3 independent experime
one-way ANOVA with Tukey post hoc test (G, I, K, M, and O). Scale bar, 100 mmsensitivity to oxidative stress for Tigar null PDAC cell lines (Fig-
ure 1M), we sought to determine the contribution of ROS to the
acquisition of the invasive phenotype of these cells. Treatment
of Tigar KO cells with the antioxidant NAC reduced migration in
both wound-scratch and transwell migration assays (Figures
5A–5D), while also limiting invasion (Figures 5E and 5F) and
collagen degradation (Figures 5G and 5H). Importantly, the
background levels of migration and invasion shown by Tigar
expressing cells were not significantly decreased by NAC treat-
ment (Figures 5A–5H). This activity in Tigar KO cells was also
clearly reduced in response to limitation of mitochondrial
ROS following treatment with mito-TEMPO (Wipf et al., 2005)
(Figures S5A and S5B), suggesting that mitochondrially derived
ROS are responsible for the increase in invasiveness in TIGAR-
deficient cells. A dose of piercidin that inhibits complex I and so
lowers mitochondrially derived ROS also decreased migration
in TIGAR-deficient cells (Figures S5C and S5D). Additional
treatment with antimycin, which re-establishes mitochondrial
ROS production by inhibiting complex III, abrogated this reduc-
tion in migration (Figures S5C and S5D), underscoring the
importance of mitochondrially derived ROS in the migratory
phenotype in TIGAR-deficient cells. Long-term treatment with
NAC (Figures 5I and 5J) also reverted the phenotype of the
cells, which regained E-CADHERIN and DUSP6 expression
and lost SNAIL expression and phosphorylated ERK. TIGAR
KO cells also regained E-CADHERIN and lost SNAIL expres-
sion after long-term treatment with mito-TEMPO (Figures S5E
and S5F). Interestingly, the ROS-dependent control of PDAC
morphology and function was highly plastic. Tigar KO cells
that reverted to epithelial morphology and reduced migration/
invasion in response to long-term antioxidant treatment were
able to regain these features following removal of the antioxi-
dant (Figures 5I–5L, S5E, and S5F). Taken together, these re-
sults show that increased ROS in response to loss of TIGAR
can promote a mesenchymal shift accompanied by increased
invasive capacity, but that modulating ROS levels can allow
the tumor cells to toggle between the two phenotypes.
In Vivo Administration of Antioxidant Can Reduce Lung
Metastasis of Tigar Null Cells
To test directly whether loss of TIGAR and ROS regulation
could have an impact on metastatic capacity, we turned to an
experimental model of metastasis in which lung colonization of
tumor cells following tail vein injection was assessed. Tigar
null PDAC cells showed a clearly increased lung colonizationay of CTR (C1–3) and TIGAR KO (K1–3) KFC PDAC cells with or without (CTR,
compared with C1–3, **p < 0.05 K1–3 with PD compared with K1–3 without
say of CTR (C1–3) and TIGAR KO (K1–3) KFC PDAC cells with or without (CTR,
–3 with PD compared with K1–3 without PD (CTR).
say of CTR (C1–3) and TIGAR KO (K1–3) KFC PDAC cells with or without (CTR,
–3 with PD compared with K1–3 without PD (CTR).
t gelatin substrate) (L) and quantification (M) of invadopodia assay of CTR and
.05 K1–3 compared with C1–3, **p < 0.05 K1–3 with PD compared with K1–3
ssay of CTR and TIGARKOKFCPDAC cells with orwithout (CTR, empty vector)
with overexpressed DUSP6 compared with K1–3 with empty vector.
nts for each cell line. Data were analyzed by two-tailed Student’s t test (C, E) or
. See also Figure S4.
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Figure 5. Tigar-Deficiency-Induced Pro-migratory Phenotype Can Be Reduced by Antioxidant NAC In Vitro
(A and B) Representative images (A) and quantification (B) of in vitrowound-scratch assay of CTR (C1–3) and TIGAR KO (K1–3) KFC PDAC cells with NAC (1 mM)
or without (CTR, no treatment). *p < 0.05 K1–3 compared with C1–3, **p < 0.05 K1–3 with NAC compared with K1–3 without NAC (CTR).
(C and D) Representative images (C) and quantification (D) of transwell migration assay of CTR (C1–3) and TIGAR KO (K1–3) KFC PDAC cells with NAC (1 mM) or
without (CTR, no treatment). *p < 0.05 K1–3 compared with C1–3, **p < 0.05 K1–3 with NAC compared with K1–3 without NAC (CTR).
(E and F) Representative images (E) and quantification (F) of transwell invasion assay of CTR (C1–3) and TIGAR KO (K1–3) KFC PDAC cells with NAC (1 mM) or
without (CTR, no treatment). *p < 0.05 K1–3 compared with C1–3, **p < 0.05 K1–3 with NAC compared with K1–3 without NAC (CTR).
(G and H) Representative images (red, phalloidin; green, nuclei; white, fluorescent gelatin substrate) (G) and quantification (H) of invadopodia assay of CTR (C1–3)
and TIGAR KO (K1–3) KFC PDAC cells with NAC (1mM) or without (CTR, no treatment). *p < 0.05 K1–3 compared with C1–3, **p < 0.05 K1–3 with NAC compared
with K1–3 without NAC (CTR).
(I) Representative images of TIGAR KOKFCPDAC cells at indicated time points continuously treatedwith NAC (1mM) and subsequent removal of NAC for 1 week
(1w no NAC).
(J) Western blot analysis of TIGAR KO (1–3) KFC PDAC cells at indicated time points continuously treated with NAC (1 mM) and subsequent removal of NAC for
1 week (1w no NAC). E-CAD, SNAIL, DUSP6, and the loading control ACTIN were detected on one blot; pERK, ERK, and the loading control VINCULIN were
detected on a separate parallel blot.
(K) Transwell migration assay of TIGAR KO (K1–3) KFC PDAC cells continuously treated with NAC or with subsequent removal of NAC. *p < 0.05 compared with
6w NAC.
(L) Transwell invasion assay of TIGAR KO (K1–3) KFC PDAC cells continuously treated with NAC or with subsequent removal of NAC. *p < 0.05 compared with
6w NAC.
(B, D, F, H, K, and L) Error bars represent mean ± SEM, n = 3 independent experiments for each cell line, and data were analyzed by one-way ANOVA with Tukey
post hoc test. w, weeks. Scale bar, 100 mm. See also Figure S5.capacity compared with Tigar wild-type cells (Figures 6A and
6B), which was decreased following treatment of cells and
mice with NAC (Figures 6A and 6B). As expected, Tigar KO me-
tastases showed increased ROS (measured by MDA staining)
(Figure S6A) that was limited following NAC treatment. Consis-
tent with results in cell lines (Figures 4 and 5), decreased
DUSP6 expression and increased phosphorylated ERKwere de-
tected in the Tigar null lung lesions, a response that was reversed
by NAC (Figures 6C–6F). Intriguingly, however, proliferation rates176 Cancer Cell 37, 168–182, February 10, 2020in the Tigar KO lung deposits were significantly lower than those
seen in the Tigar wild-type lesions, a response that was also
reversed, to some extent, by NAC treatment (Figures 6G and
6H). While the data are consistent with a ROS-driven increase
in the ability of Tigar null PDAC cells to colonize the lung following
tail vein injection, this decrease in proliferation may indicate
that maintenance of high ROS levels becomes detrimental to
the proliferation of the lung lesions once the cells have become
established at this site.
Figure 6. Tigar-Deficiency-Induced Metastasis Can Be Decreased by Antioxidant NAC In Vivo
Lung tissues from animals 2 weeks after tail vein injection of CTR and TIGAR KO PDAC KFC cell lines with and without NAC treatment (1 g/L drinking water; CTR,
drinking water without NAC).
(A and B) (A) H&E staining of lung tissues and (B) quantification of tumor area in lung tissues.
(C and D) DUSP6 staining (C) and quantification (D).
(E and F) pERK staining (E) and quantification (F).
(G and H) Ki67 staining (G) and percentage of Ki67-positive cells (H). (B,D,F,H) *p < 0.05 KO compared with CTR, **p < 0.05 KO with NAC compared with KO
without NAC (CTR).
(B, D, F, and H) Error bars represent mean ± SEM, and data were analyzed by one-way ANOVA with Tukey post hoc test. Scale bar, 100 mm. See also Figure S6.Dynamic Changes in TIGAR Expression during Cancer
Progression
Immunohistochemical analysis of TIGAR at various stages of
PDAC tumorigenesis showed an increase in TIGAR expression
during the early stages of tumor development in both the KFC
mouse model (Figures 7A and 7B) and human PDAC samples
(Figures 7C and 7D), consistent with a role for TIGAR in limiting
ROS and promoting the survival of these preinvasive cells.
However, in both mouse and human cancers, progression to
invasive primary tumors was accompanied by a clear decrease
in TIGAR expression (Figures 7A–7D), consistent with the selec-
tion for cells with higher ROS and higher invasive capacity during
these stages of tumorigenesis. Interestingly, TIGAR levels were
found to be slightly increased in the metastatic deposits from
these tumors, consistent with a role for TIGAR re-expression in
limiting ROS and supporting proliferation in the established
metastases. Analysis of ROS levels in these different tumor
stages showed the expected correlation between high TIGAR
and low ROS in PDAC lesions, with higher ROS accumulation
in later stage, invasive tumors expressing lower TIGAR levels
(Figures 7E and 7F).
DISCUSSION
Many studies in various models have indicated a role for both
ROS limitation and ROS promotion in driving tumor initiation
and metastatic spread (Arnandis et al., 2018; Ishikawa et al.,2008; Le Gal et al., 2015; Lignitto et al., 2019; O’Leary et al.,
2015; Piskounova et al., 2015; Porporato et al., 2014; Radisky
et al., 2005; ten Kate et al., 2006; Wiel et al., 2019; Woo et al.,
2012). We showed previously that the antioxidant protein
TIGAR can support cell survival and proliferation during tissue
regeneration and adenoma development, and several studies
have shown increased TIGAR expression in various tumor
types (Cheung et al., 2013; Lee et al., 2014). Using a pancre-
atic tumor model, we show that deletion of Tigar drives
increased ROS and a decrease in the development of prema-
lignant PanIN lesions, consistent with an enhanced prolifera-
tive capacity of cancer cells with higher TIGAR expression.
However, despite the limitation of tumor initiation, Tigar null
lesions showed an increased ability to metastasize, especially
to the lung. Enhancing ROS through loss of NRF2 in a similar
tumor model also limited PanIN development (DeNicola et al.,
2011) while promoting enhanced metastasis to the lung.
Increased metastatic capacity of the Tigar null cells was
mirrored by the acquisition of a more mesenchymal pheno-
type, activation of ERK signaling through the decreased
expression of the phosphatase Dusp6/MKP-3, and increased
migration and invasion in vitro. Activation of ERK, while asso-
ciated with tumor proliferation, migration, and survival,
can also limit growth through mechanisms such as senes-
cence or increased sensitivity to other stresses, especially
when hyperactivated in the context of an increase of ROS
level (Cagnol and Chambard, 2010; Hong et al., 2018;Cancer Cell 37, 168–182, February 10, 2020 177
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Joneson and Bar-Sagi, 1999; Woods et al., 1997). It seems
likely that DUSP6 expression can be fine-tuned to modulate
ERK at different stages of tumor progression and that this
ability is lost in TIGAR null cells. Interestingly, expression of
the phosphatase Dusp6/MKP-3 has been shown previously
to be lost in some human PDAC samples, and its expression
can be regulated by ROS (Chan et al., 2008; Furukawa et al.,
1998). ROS limitation reversed the more aggressive pheno-
type of these cells and reduced the experimental metastatic
capacity in vivo.
Our data indicate a complex role for ROS in regulating cancer
initiation, growth, and metastatic progression that may help to
explain some of the apparently contradictory results seen in pre-
vious studies. It is clear that loss of antioxidant defense can limit
some stages of tumor development while enhancing others. The
exact response of any tumor system is likely to depend on
numerous factors, including the cell of origin, the genetic land-
scape of the tumor cell, and the tumor environment. For
example, a failure to limit ROS is clearly detrimental to the met-
astatic ability of melanoma and lung tumor cells (Le Gal et al.,
2015; Lignitto et al., 2019; Piskounova et al., 2015; Wiel et al.,
2019), while ROS limitation is associated with enhanced EMT
in breast cancer models (Dong et al., 2013). The contribution of
different environments in determining the response to ROS is
also evident in the increased metastasis seen in both Tigar and
Nrf2 deletion models. In cell culture models, the ability of tumor
cells to survive matrix detachment—an event that is thought to
mirror the success of cells in surviving in the circulation—has
also been related to an ability to modulate metabolism to limit
ROS (Labuschagne et al., 2019; Schafer et al., 2009; Jiang et
al., 2016). However, in the PDAC model described here,
enhanced ROS clearly promotes the acquisition of certain
mesenchymal phenotypes that can be important in metastasis
(Chaffer et al., 2016).
The differential ability of ROS regulation to modulate
different steps in the progression of a single tumor type high-
lights the challenges that would accompany the development
of anti- or pro-oxidant approaches for cancer therapy.
Although the response to ROS may reflect the overall level
of oxidative stress, previous studies have shown that different
ROS species, or different locations of ROS production in cells,
can have differential effects on proliferation and survival (Goh
et al., 2011; Ishikawa et al., 2008; Liou et al., 2016; Schriner
et al., 2005). Whether the responses to ROS during tumor pro-
gression reflect overall levels of ROS, differences in the cell’s
ability to respond to ROS or a subtler contribution of different
types of ROS that may be controlled by different pathways
remain to be determined. We note that in this and previous
studies, TIGAR was shown to more effectively limit mitochon-
drial than cytosolic ROS (Cheung et al., 2016). Whereas in in-
testinal regeneration studies, this activity clearly functioned toFigure 7. TIGAR Expression in PDAC and Metastasis
(A and B) TIGAR staining (A) and quantification (B) of mouse KFC PDAC tissues.
(C and D) TIGAR staining (C) and quantification (D) of human PDAC tissue microa
(E and F) MDA staining (E) and quantification (F) of mouse KFC PDAC tissues at va
(B, D, and F) Error bars represent mean ± SEM, and data were analyzed by on
**p < 0.05 compared with invasive. Scale bar, 100 mm.support cell survival and proliferation (and thereby tissue
repair), in the context of PDAC progression, the limitation of
mitochondrial ROS by TIGAR dampens the activation of
signaling pathways that promote migration and invasion.
Our study underscores the multifaceted role of ROS in con-
trolling disease progression. Therapies that either increase or
decrease ROS could lead to very different outcomes in different
tumor types or at different stages of cancer progression. In in-
testinal adenomas, which are not metastatic, deletion of TIGAR
limits the development of the tumor and improves survival.
However, despite the delay in premalignant tumor development
in the PDACmodel, the capacity of these cells to metastasize is
enhanced by TIGAR deletion and decreases overall survival.
We speculate that while therapies to increase ROS could be
beneficial in some contexts (for example, in lung cancer or
melanoma), an initial effect of such treatment on locally
confined tumors (such as pancreas) could lead to an inadver-
tent increase in invasiveness, which is the more likely cause
of death. Additional studies to determine the roles of different
antioxidants in other genetic mouse models of cancer will
be important to inform therapy decisions relating to ROS level
manipulation and the timing/sequence of combined treatments
involving ROS.
In the PDAC model, ROS can be a powerful regulator of cell
phenotype and behavior, allowing cells to toggle between an
epithelial/less invasive state to a more mesenchymal/invasive
state. The plasticity of this switch is of interest, suggesting
that the response is driven by events such as modulation of
chromatin modifications that can be reversed when the oxidative
signal is removed, and it is important to note that the switch in
phenotype requires several weeks in culture in the presence or
absence of an antioxidant. A wealth of previous data shows
that a switch to a more mesenchymal phenotype can promote
successful metastasis (Chaffer et al., 2016). However, the ability
to reverse this transition—to undergomesenchymal-to-epithelial
transition—has been linked with the success of cancer cells to
expand and proliferate once they have reached and become es-
tablished at a distant metastatic site (Lu and Kang, 2019; Tsai
et al., 2012). The ability of ROS regulation to toggle cells between
these two states suggests this could be an importantmechanism
to regulatemany steps ofmalignant progression. Our analyses of
TIGAR expression correlate with a role for ROS limitation in the
outgrowth of both the premalignant and the metastatic lesions
(selecting for cells with high TIGAR expression), but a contribu-
tion of increased ROS in cells during the process of invading or
moving to a distant site (selecting for cells with lower TIGAR
expression). Our data also hint at a role for a second round of
TIGAR upregulation to support proliferation of cells once they
are established at the metastatic site. Further studies will be
required to understand the mechanisms of TIGAR regulation
that can result in this complex pattern of expression.rray. (B,D) *p < 0.05 compared with normal, **p < 0.05 compared with PanIN1.
rious stages of tumor development. Ab., abdominal muscle; Met., metastasis.
e-way ANOVA with Tukey post hoc test. (F) *p < 0.05 compared with PDAC,
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
In Vivo Animal Studies
All animal experiments were performed under the Animals (Scientific Procedures) Act 1986 in accordance with UK Home Office li-
censes (Project License 70/8645, P319AE968) and the EU Directive 2010 and sanctioned by local ethical review process (University
of Glasgow and The Francis Crick Institute). Mice were housed in an area free of pathogens as defined by FELASA recommendations
in IVC ages at 5 per cage at constant temperature (19-23C) and humidity (55% ± 10%), with a 12-hour light/dark cycle (lights on at
7:00 am) and were allowed access to food and water ad libitum. Mice were allowed to acclimatize for at least 2 days (for mice bred on
site) or 7 days (for imported mice) prior to the experiment and were randomly assigned to experimental groups. For the PDAC
GEMMs, both male and female mice were used, roughly matched between CTR and KO groups. For the tail vein lung colonization
models only female mice were used. Mice had not been involved in any previous procedures.
Transgenic Mouse Models for Pancreatic Ductal Adenocarcinoma (PDAC)
Trp53+/LSL-R172H, Kras+/LSL-G12D, Trp53+/fl, Pdx1-Cre strains were interbred to obtain KC (Pdx1-Cre; Kras+/LSL-G12D), KFC (Pdx1-Cre;
Kras+/LSL-G12D; Trp53+/fl), and KPC (Pdx1-Cre; Kras+/LSL-G12D; Trp53+/LSL-R172H) mice (Hingorani et al., 2005; Jonkers et al., 2001). To
introduce TIGAR deficiency in these models, TIGARfl/fl strain (Cheung et al., 2016) was used to breed into the above strains to obtain
Tigarfl/+ or Tigar+/+ for control (CTR) and Tigarfl/fl for Tigar knockout (KO) in KC, KFC and KPC in a mixed background. Pdx1-Cre;
Kras+/LSL-G12D; Trp53+/LSL-R270H; Nrf2-/- (DeNicola et al., 2011) mice were also used. Mice were monitored two times weekly and tis-
sues were collected when exhibiting symptoms of PDAC (Hingorani et al., 2005).
Lung Metastasis Model
2X105 PDAC KFC cells per mouse (nR4 in each group) in 100ml PBS were injected (tail vein) into athymic nu/numice (Jackson Lab-
oratory). After 14 days, lung tissues were collected for histological analysis. For antioxidant treatment, a week before the injection
NAC (N-Acetyl-L-cysteine, Sigma A7250) was administered to the mouse (1g/L drinking water, pH 7) and throughout the duration
of experiment. PDAC cells were pre-treated overnight with NAC before trypsinized and used at the day of injection.e2 Cancer Cell 37, 168–182.e1–e4, February 10, 2020
Cell Cultures
PDAC tumor cell lines were derived from the KFC tumors from three TIGAR WT and three TIGAR KO animals. Tumor tissues were
collected in PBS with 1% penicillin-streptomycin and then finely minced. Minced tissues were then incubated with collagenase
type 1 (200U/ml, Gibco) and dispase (2.4U/ml, Gibco) in HBSS for 1 hour in 37C for cell dissociation. After washing 2X in HBSS,
cell pellets were resuspended and grown in growth media (Dulbecco’s modified Eagle medium containing 10% fetal bovine serum,
2 mM l-glutamine, 1% penicillin-streptomycin).
METHOD DETAILS
Transwell Migration/Invasion Assays
Transwell Migration assays (Corning BioCoatTM Control Insert-No ECM, 8 micron pore size) and Invasion assays (Corning Bio-
CoatTM Matrigel Invasion chamber) were performed according to the manufacturer’s instructions. Briefly, cells were pre-treated
overnight in 1% serum with or without the indicated drugs/treatments before seeding onto the upper chamber of the transwell the
following day in the presence of the drug treatment. Media with 10% serum (with andwithout the drugs) were used in the lower cham-
ber. After 16 hours, cells that remained on the top of the membrane were removed by a cotton-tipped applicator. Cell that were
migrated/invaded to the bottom of the insert were then fixed in 70% ethanol and stained with 0.5% Crystal Violet. Migrated/Invaded
cells were photographed under an inverted microscope, quantified using ImageJ, and represented as percentage of total area.
Wound Scratch Assay
Confluent monolayer of cells was scratched using a p20 pipette tip to create a scratch. Debris were removed by washing the cells
gently with 2X completemedia. Image were taken at the start of the assay and after 16 hours under a phase contrast microscope. The
width of the gap was measured by ImageJ and the reduction of the width is represented as percentage (%) wound closure.
Histology and Immunohistochemistry
Tissues were fixed in 10% neutral buffered formalin and were embedded in paraffin and processed by standard histological
techniques. PanIN was defined by previously published guildelines in genetically modified mouse models of PDAC. Briefly, PanIN
is a lesion that arises in native pancreatic ducts measuring <1 mm and not on a background of acinar-ductal metaplasia. PanIN le-
sions are graded as PanIN-1, 2 or 3 according to the cytological and architectural characteristics as described previously (Hruban
et al., 2001). Quantitation of PanIN number was done on 5 of 20X fields of view from at least 4 mice. Heat induced epitope retrieval
with sodium citrate buffer (Antigen Unmasking Solution, Citric Acid Based, Vector Laboratories, cat # H-3300) followed by blocking
endogenous peroxidase and Avidin/Biotin (BLOXALL Endogenous Peroxidase and Alkaline Phosphatase Blocking Solution, Vector
Laboratories, cat # SP-6000) were used for immunohistochemistry prior to primary antibody incubation (diluted in 10% normal horse
serum in 1XTBST, 4C overnight). For immunohistochemistry, primary antibodies used were anti-Ki67 (1:1000 Thermo Scientific
SP6), anti-MDA (1:300, Abcam Ab6463), anti-TIGAR (1:500 Millipore AB10545), anti-phospho-ERK (Cell Signalling), anti-DUSP6
(1:300 Abcam Ab76310), anti-Snail (1:300 Cell Signalling #3879), anti-Slug (1:300 Cell Signalling #9585), anti-E-Cadherin (1:300
Cell Signalling), anti-Vimentin (1:300, Cell Signaling #5741), anti-Cytokeratin 19 (CK-19) (1:500, Abcam Ab52625). Expression levels
were scored based on staining intensity and area of tumor cells using a weighted histoscore calculated from the sum of (13%weak
staining) + (2 3% moderate staining) + (3 3% strong staining).
Human TMA Analysis
TMA of human pancreatic cancer was obtained from US Biomax (PA2081b) and was stained with anti-human TIGAR antibody (Ben-
saad et al., 2006).
Cell Death, ROS Measurement, and Western Blot Analysis
Cell death was quantified using LIVE/DEAD Viability Kit (Molecular Probes) 18 hours after adriamycin (1mg/ml, Sigma) alone or with
either NAC (1mM) or recombinant TIGAR (rTIGAR, 5mg/ml, Peprotech). Mito tempo (50mM, Sigma SML0737), Piericidin (1mM, Cay-
men Chemical 15379), Antimycin A (1mM, Caymen Chemical 19433) and PD98059 (50mM, Tocris cat# 1213) were used at the indi-
cated times and duration. Mitochondrial ROSwasmeasured byMitoSOXRedMitochondrial Superoxide Indicator (Invitrogen cat #
M36008). Protein lysates were isolated in RIPA-buffer (Millipore) with complete protease inhibitors (Roche) and phosphatase inhibitor
cocktail (Thermo Fisher Scientific), volume adjusted according to protein concentration measurements (Quick StartTM Bradford 1X
Dye Reagent, Bio-Rad, Cat #500-0205), separated using precast NuPAGE 4-12% Bis-Tris Protein gels (Invitrogen, Life Technolo-
gies), and transferred to nitrocellulosemembranes. ECL chemiluminescence detection kits (Pierce) with appropriate species-specific
horseradish peroxidaseconjugated secondary antibodies were used to detect the proteins. Each blot shows one representative out
of at least three. Antibodies used are : anti-TIGAR (1:1000, Santa Cruz sc-67273), anti-p-ERK1/2 Thr202/204 (1:1000, Cell Signaling),
anti-DUSP6 (1: 500 Abcam Ab76310), anti-Snail (1:1000, Cell Signaling #3879), anti-Slug (1:1000, Cell Signaling #9585), anti-E-Cad-
herin (1:5000, Cell Signaling #3195), anti-p-FAK Tyr576/577 (1:1000, Cell Signaling #3281), anti-p-Akt Ser 473 (1:1000, Cell Signaling
#13038), anti-GCLC (1:1000 Abcam Ab190685), anti-HO1 (1:500, Santa Cruz sc10789), anti p-NF-kB p65 (1:1000, Cell Signaling
#3033), anti-p-Src family (1:500, Cell Signaling #6943), anti-p-Stat3 Tyr 705 (1:1000, Cell Signaling #9145), anti-Actin (1:10000, Ab-
cam Ab20272), anti-ERK (1:1000, Cell Signaling #9102), anti-BACH1 (1:1000, Santa Cruz sc-271211), anti-BNIP3 (1:1000, CellCancer Cell 37, 168–182.e1–e4, February 10, 2020 e3
Signaling #3769), anti-MET (1:1000, Cell Signaling #8198), anti-Vinculin (1:1000, Santa Cruz sc-25336), anti-Histone H3 (1:1000, Cell
Signaling #9715).
Transfection of siRNA and cDNA
Re-expression of DUSP6 was achieved by transfecting a mouse tagged ORF clone of DUSP6 (Origene, cat#MR222688) with empty
vector as control. Knockdown of ERK1/2 was achieved by transfecting siRNA targeting ERK1/2 (Origene, cat#SR412074, 412814)
with the corresponding scrambled siRNA as negative control. Transfection was performed using Lipofectamine 2000 for DNA (Invi-
trogen) or Lipofectamine RNAiMAX for siRNA (Invitrogen) according to the manufacturer’s instructions.
Immunofluorescence Staining
Cells were fixed in 4% paraformaldehyde in 1X PBS, followed by permeabilization with 0.4% Triton X 100 in 1XPBS with 10% normal
donkey serum. Primary antibody was prepared in 1XPBS with 0.4% Triton X-100 and 2% normal donkey serum. Antibody used
were E-Cadherin (1:500, BD Biosciences, #610182) and Vimentin (1:500, Cell Signaling, #5741). Fixed cells were incubated overnight
in 4Cwith the primary antibody, washed 3X in 1XPBS, followed by incubation of secondary antibody for 1 hour at room temperature
(1:500 in 1XPBS with 0.4% Triton X-100 and 2% normal donkey serum, Alexa Fluor 488 donkey anti-mouse Alexa Fluor 488 or Alexa
Fluor 594 donkey anti-rabbit, Thermo Fischer Scientific).
Invadopodia Assay
Invadopodia assay (QCMTM Gelatin Invadopodia Assay, Millipore) was performed according to the manufacturer’s instructions.
Briefly, glass chamber slides were coated with Poly L Lysine, activated by a diluted glutaldehyde solution, and then fluorescently
coated with fluorescent gelatin as the substrate for invadopodia. After disinfecting with 70%alcohol and quenching of free aldehydes
with growth medium, cells were seeded onto the gelatin surface for 16 hours in complete media. Cells were then fixed in 4% form-
aldehyde in DPBS and visualized by nuclear (DAPI) and cytoskeleton staining (TRITC-Phalloidin) by fluorescent microscopy.
Degraded area/puncta of fluorescent gelatin (devoid of green fluorescence) indicated the presence of invadopodia and was quan-
tified per number of cells (at least 100 cells were analysed per experiment).
Metabolomics
Cells were seeded in 6 well plates at a density of 1x105 in DMEM. Themedia was refreshed after 24 hours and replaced after 48 hours
with media containing 1,2-13C2-glucose. Cells were cultured in this media for 5 hours before harvesting the cells for metabolomics
and isotope tracing analysis. Cells were harvested by removing the media and rinsing with cold PBS before cells were lysed by
adding cold (-20C) extraction buffer containing methanol, acetonitrile and water (50:30:20) directly on the cells followed by scraping
and collecting everything in a clean 1.5 ml centrifuge tube. The tubes were vortexed for 1 min before centrifugation at full speed for
15 minutes at 4C. The supernatant was collected into mass spectrometry tubes and analysed by liquid chromatography high
resolution mass spectrometry as described before (Labuschagne et al., 2019). Briefly, liquid chromatography was performed on a
Dionex Ultimate 3000 LC system coupled to a Q Exactive mass spectrometer (Thermo Scientific). Metabolites were separated on
a Sequant ZIC-pHILIC column (2.1 x 150 mm, 5mM) (Merck) with mobile phase A consisting of 20 mM (NH4)2CO3, 0.1% NH4OH
in H2O and mobile phase B consisting of 100% acetonitrile. A linear gradient from 80% to 20% A was applied over 17 minutes at
a flow rate of 200 ul/min. Eluents were ionized in a HESI probe connected to the Q Exactive which scanned a mass range between
75 and 1000 m/z with polarity switching. Data were analysed with using Thermo TraceFinder software.
QUANTIFICATION AND STATISTICAL ANALYSIS
Datawere analysed usingGraphPad Prism 7 software (GraphPad Software). The survival datawere analysed by log-rankMantel-Cox
test. Fisher’s exact test was used to compare frequency of metastasis. Other data represent mean values ± SEM from at least three
independent experiments (nR 3). Student’s t test (comparisons between two groups), one-way ANOVA with Tukey post hoc (com-
parisons of three or more groups with one independent variable) were used as indicated in the legends. p <0.05 was considered sta-
tistically significant.
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